TempraMed Technologies Ltd. News Releases

TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives

Thu, 09 Jul 2026 07:00:00 -0400

Acceptance of TempraMed's products by Meuhedet Health Services strengthens TempraMed's B2B institutional commercialization strategy as the Company advances reimbursement initiatives and expands relationships with leading healthcare organizations globally HighlightsMeuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed's flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now...

TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market

Mon, 06 Jul 2026 07:00:00 -0400

HighlightsTempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir TradingKuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medicationsLOI includes minimum annual purchase commitments in Year 1Expands TempraMed's footprint across the Middle East and supports broader regional commercialization strategyPotential future expansion includes VIVI Med™, VIVI Epi™, and VIVI Cap Smart™...

TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels

Tue, 30 Jun 2026 03:05:00 -0400

Integration into McKesson's Medical-Surgical Solutions marketplace serving a nationwide customer base Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio...

TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia

Fri, 26 Jun 2026 16:10:00 -0400

Strategic Saudi partnership with Rawafed Health International Company targets one of the region's largest diabetes and injectable-therapy markets, supported by leading healthcare infrastructure, pharmacy access in the region Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it...

TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally

Thu, 04 Jun 2026 07:00:00 -0400

Expands Latin America presence with strategic partnership with Mobil Saúde and builds on TempraMed's recently granted Brazilian patent portfolio HighlightsTempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world's largest markets for diabetes, GLP-1 therapies, and temperature-sensitive biologics1. Diabetes market alone reached USD $2.15 Billion in 2025 Partnership builds on TempraMed's recently granted Brazilian patent...

TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications

Fri, 22 May 2026 11:57:00 -0400

Broadcast across the United States brings attention to the under-addressed risk of medication degradation caused by heat exposure and the real-world need for better medication protection and tracking Vancouver, British Columbia--(Newsfile Corp. - May 22, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed a medical technology innovator transforming how...

TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product

Thu, 14 May 2026 03:00:00 -0400

Another major milestone in its continuous global IP strategy, advancing protection of VIVI Cap Smart across international markets HighlightsGranted Patent covers the design of VIVI Cap Smart™ across major international, growing marketStrengthens the Company's intellectual property position in one of the world's largest healthcare and consumer marketsSupports commercialization strategy and strategic discussions with appliance manufacturers Design term extends through May 16, 2039Company enters...

TempraMed Announces Continuance into Ontario

Wed, 29 Apr 2026 16:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has continued out of the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) into the provincial jurisdiction of Ontario under the Business Corporations Act (Ontario)...

TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product

Tue, 07 Apr 2026 07:00:00 -0400

Grant in Brazil marks a major milestone in global IP strategy, advancing protection of its VIVI Box across key international markets HighlightsBrazilian patent officially granted by the Brazilian Patent Office Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer marketsSupports commercialization strategy and strategic...

TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure

Mon, 30 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI"), dated March 22, 2026, with TEM Consulting International S.A. ("TEM") a leading healthcare logistics and consultancy company based in the Panama, with respect to the...